ESC 365 - Favourable safety profile of S62798, a potent TAFIa (activated thrombin-activatable fibrinolysis inhibitor) inhibitor, in first-in-man study in healthy subjects

ESC Premium Access

Favourable safety profile of S62798, a potent TAFIa (activated thrombin-activatable fibrinolysis inhibitor) inhibitor, in first-in-man study in healthy subjects

Session: Advances in Chronic Thromboembolic Pulmonary Hypertension

Topic: Clinical

Speaker: Mrs F. Petit Dop (Suresnes, FR)

Event: ESC Congress 2020

Congress Presentation

About the speaker

Mrs Florence Petit Dop

International Research Institute Servier (IRIS), Suresnes (France)

0 follower

2 more presentations in this session

Accurate and efficient non-invasive strategy for early identification of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism (InShape II study)

Speaker: Doctor E. Klok (Leiden, NL)

De-escalation/discontinuation of oxygen-therapy and medication is feasible and safe in chronic thromboembolic pulmonary hypertension patients treated with balloon pulmonary angioplasty

Speaker: Doctor M. Kimura (Tokyo, JP)

Access the full session

Advances in Chronic Thromboembolic Pulmonary Hypertension

Speakers: Mrs F. Petit Dop, Doctor E. Klok, Doctor M. Kimura

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

ESC 365 is supported by